Tyler Sandow, MD
- Physician, Southshore Region
- 1514 Jefferson Hwy, New Orleans, LA, 70121
For additional information or to make an appointment, click here.
Overview
Overview
- I chose to become a doctor based on a desire to have a meaningful impact in someone's life for the better, to help in a time of need. As an interventional radiologist, I have the ability to use cutting-edge, minimally-invasive techniques to treat conditions throughout the body, such as cancer, bleeding, blood clots, fibroids, prostate enlargement, liver disease, leg pain, infection, among other conditions; all while leaving behind no more than a band-aid. The goal of my practice is not only to provide optimal care of patients, but to also make sure that all my patients are well-informed about treatment plans and therapeutic options as well as comfortable throughout the entire process from initial consultation to follow-up care. Additionally, I think it's incredibly important to maintain open dialogue with referring providers to keep them updated on their patients.I have been fortunate to spend almost my entire life in Louisiana. After graduating from LSU, I received my medical degree from LSUHSC-Shreveport. I completed a residency in Diagnostic Radiology at Ochsner Medical Center. Following residency, I received fellowship training at Georgetown University Hospital, gaining invaluable experience in interventional oncology, portal hypertension, peripheral vascular disease, and uterine fibroid embolization.I have published several papers in the field of interventional oncology in journals such as Radiology and Journal of Vascular and Interventional Radiology. In collaboration with transplant surgery, I have been a co-investigator on several grant funded trials. Additionally, our research on hepatocellular carcinoma has been presented at multiple national and international meetings. In 2018, I was privileged to receive the Society of Interventional Radiology Fellow Research Award.I feel that patients need to be actively involved in their care (i.e. in the driver seat). It is the objective of the physician, as an expert in the disease process, to help guide the patient towards appropriate care. However, I think that the more engagement from the patient will help lead to better outcomes.
Publications
Selected publications
-
2023Gaps in care planning and delivery for patients with liver cancer: Baseline assessment for implementation of 4R Oncology model. Journal of Clinical Oncology. 41.
-
2023Racially Disparate Disease Progression Rates in Early-Stage Hepatocellular Carcinoma Patients. American Journal of Transplantation. 23:S730-S730.
-
2023Single-Center Outcomes of First-Cycle Yttrium-90 for Bridge to Liver Transplantation in Hepatocellular Carcinoma Patients. American Journal of Transplantation. 23:S729-S730.
-
2022Critical Variables Driving Patient Outcomes in Early- Stage Hepatocellular Carcinoma with Elevated Risk Factors. American Journal of Transplantation. 23:S67-S67.
-
2022Single-Center Outcomes of First-Cycle Yttrium-90 for Bridge to Liver Transplantation in Hepatocellular Carcinoma Patients. American Journal of Transplantation. 23:S36-S36.
-
2022Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy. Frontiers in Oncology. 12.
-
2020AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype. Journal of the American Society of Nephrology. 31:1688-1695.
-
2020Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients. American Journal of Transplantation. 20:492-493.
-
2020Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation. American Journal of Transplantation. 20:492-492.
-
2020Expansion of Immunosuppressive Cell Populations Associates with Tumor-Derived Exosome Shedding in Early-Stage HCC Patients undergoing Locoregional Therapy. American Journal of Transplantation. 20:60-60.
-
2019Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. JVIR: Journal of Vascular and Interventional Radiology. 30:995-1003.
-
2019Evaluation of Liver Function and Biomarkers Predicts Tumor Progression in Treatment-Naive Hepatocellular Carinoma Patients.. American Journal of Transplantation. 19:767-767.
-
2019Modified BALAD Score Predicts Incomplete Locoregional Therapy Treatment in Hepatocellular Carcinoma Patients. American Journal of Transplantation. 19:72-73.
-
2019Pre-Treatment Lymphocyte Status in HCC Patients Associates with DEB-TACE Response and Correlates with Increased Regulatory Immune Cells.. American Journal of Transplantation. 19:762-762.
-
2019
-
2018
-
2018T Cell Lineage Imbalance and Regulatory Immune Populations in HCC Patients Undergoing Downstaging While Waitlisted for Liver Transplantation.. American Journal of Transplantation. 18:722-722.
-
2017Doppler Characteristics of Recurrent Hepatic Artery Stenosis. Journal of Ultrasound in Medicine. 36:209-216.
-
2017Effect of Embolization History and Tumor Treatment Response on Plasma TGF beta in HCC Patients Listed for Liver Transplantation. American Journal of Transplantation. 17:433-433.
-
2017Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology. The Ochsner Journal. 17:412-416.
-
2017Left Atrial Air Embolism Following Computed Tomography-Guided Lung Biopsy. The Ochsner Journal. 17:141-143.
-
2017Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant. American Journal of Transplantation. 17:436-436.
-
2017Predicting Recurrence Prior to Transplant: The Response of HCC to Chemoembolization. American Journal of Transplantation. 17:436-437.
-
2016Elevated Lung Shunt Fraction as a Prognostic Indicator for Disease Progression and Metastasis in Hepatocellular Carcinoma. JVIR: Journal of Vascular and Interventional Radiology. 27:804-811.
-
2016Elevated Lung Shunt Fraction as an Independent Predictor of Local Disease Progression and Metastasis in Hepatocellular Carcinoma.. American Journal of Transplantation. 16:461-462.
-
2015Clinical Images A Quarterly Column Rare Neonatal Look at Chiari II Thoracic Myelomeningocele. The Ochsner Journal. 15:8-10.